

# John W Stevens

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7117678/publications.pdf>

Version: 2024-02-01

60  
papers

2,307  
citations

186265

28  
h-index

223800

46  
g-index

61  
all docs

61  
docs citations

61  
times ranked

3309  
citing authors

#	ARTICLE	IF	CITATIONS
1	Worldwide relative smoking prevalence among people living with and without HIV. <i>Aids</i> , 2021, 35, 957-970.	2.2	32
2	Prevalence of respiratory conditions among people who use illicit opioids: a systematic review. <i>Addiction</i> , 2020, 115, 832-849.	3.3	25
3	Pharmacological thromboprophylaxis to prevent venous thromboembolism in patients with temporary lower limb immobilization after injury: systematic review and network meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 422-438.	3.8	27
4	How Uncertain is the Survival Extrapolation? A Study of the Impact of Different Parametric Survival Models on Extrapolated Uncertainty About Hazard Functions, Lifetime Mean Survival and Cost Effectiveness. <i>Pharmacoeconomics</i> , 2020, 38, 193-204.	3.3	25
5	Reply to Thromboprophylaxis in temporary lower limb immobilization: Extrapolate with care. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 519-520.	3.8	0
6	Thromboprophylaxis in lower limb immobilisation after injury (TiLLI). <i>Emergency Medicine Journal</i> , 2020, 37, 36-41.	1.0	25
7	A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement. <i>Medical Decision Making</i> , 2019, 39, 899-909.	2.4	28
8	Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies. <i>Pharmacoeconomics</i> , 2019, 37, 1537-1551.	3.3	12
9	Decision-analysis modelling of the effects of thromboprophylaxis for people with lower limb immobilisation for injury. <i>British Journal of Haematology</i> , 2019, 186, 166-168.	2.5	1
10	Dexamethasone implant for non-infectious uveitis: is it cost-effective?. <i>British Journal of Ophthalmology</i> , 2019, 103, 1639-1644.	3.9	4
11	Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. <i>Health Technology Assessment</i> , 2019, 23, 1-328.	2.8	35
12	Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2019, 23, 1-190.	2.8	17
13	Incorporating Genuine Prior Information about Between-Study Heterogeneity in Random Effects Pairwise and Network Meta-analyses. <i>Medical Decision Making</i> , 2018, 38, 531-542.	2.4	14
14	Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 1143-1151.	3.3	0
15	A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence. <i>Research Synthesis Methods</i> , 2018, 9, 148-162.	8.7	19
16	Using Evidence from Randomised Controlled Trials in Economic Models: What Information is Relevant and is There a Minimum Amount of Sample Data Required to Make Decisions?. <i>Pharmacoeconomics</i> , 2018, 36, 1135-1141.	3.3	2
17	Assessing prognosis and prediction of treatment response in early rheumatoid arthritis: systematic reviews. <i>Health Technology Assessment</i> , 2018, 22, 1-294.	2.8	16
18	Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods. <i>Medical Decision Making</i> , 2017, 37, 377-390.	2.4	79

#	ARTICLE	IF	CITATIONS
19	Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2017, 35, 805-815.	3.3	8
20	A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy. <i>Pharmacoeconomics</i> , 2016, 34, 1023-1038.	3.3	21
21	Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis. <i>Bone</i> , 2016, 89, 52-58.	2.9	59
22	Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. <i>Health Technology Assessment</i> , 2016, 20, 1-326.	2.8	41
23	A systematic review and economic evaluation of bisphosphonates for the prevention of fragility fractures. <i>Health Technology Assessment</i> , 2016, 20, 1-406.	2.8	62
24	Preventing the progression to Type 2 diabetes mellitus in adults at high risk: A systematic review and network meta-analysis of lifestyle, pharmacological and surgical interventions. <i>Diabetes Research and Clinical Practice</i> , 2015, 107, 320-331.	2.8	112
25	Nalmefene for Reducing Alcohol Consumption in People with Alcohol Dependence: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2015, 33, 833-847.	3.3	27
26	Systematic review and economic modelling of the clinical effectiveness and cost-effectiveness of art therapy among people with non-psychotic mental health disorders. <i>Health Technology Assessment</i> , 2015, 19, 1-120.	2.8	71
27	Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation. <i>Health Technology Assessment</i> , 2015, 19, 1-102.	2.8	43
28	Prehospital Noninvasive Ventilation for Acute Respiratory Failure: Systematic Review, Network Meta-analysis, and Individual Patient Data Meta-analysis. <i>Academic Emergency Medicine</i> , 2014, 21, 960-970.	1.8	52
29	Cost-Effectiveness of Cilostazol, Naftidrofuryl Oxalate, and Pentoxifylline for the Treatment of Intermittent Claudication in People With Peripheral Arterial Disease. <i>Angiology</i> , 2014, 65, 190-197.	1.8	18
30	Routine echocardiography in the management of stroke and transient ischaemic attack: a systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2014, 18, 1-176.	2.8	34
31	The 3Mg trial: a randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma. <i>Health Technology Assessment</i> , 2014, 18, 1-168.	2.8	30
32	What is the clinical effectiveness and cost-effectiveness of cytisine compared with varenicline for smoking cessation? A systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2014, 18, 1-120.	2.8	60
33	Heart-type fatty acid binding protein as an early marker for myocardial infarction: systematic review and meta-analysis. <i>Emergency Medicine Journal</i> , 2013, 30, 280-286.	1.0	40
34	Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2013, 31, 653-661.	3.3	18
35	Remote monitoring after recent hospital discharge in patients with heart failure: a systematic review and network meta-analysis. <i>Heart</i> , 2013, 99, 1717-1726.	2.9	114
36	Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. <i>BMJ Open</i> , 2013, 3, e003250.	1.9	41

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of presentation versus delayed troponin testing for acute myocardial infarction. <i>Heart</i> , 2012, 98, 1498-1503.	2.9	40
38	Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. <i>British Journal of Surgery</i> , 2012, 99, 1630-1638.	0.3	94
39	Routine Antenatal Anti-D Prophylaxis in Women Who Are Rh(D) Negative: Meta-Analyses Adjusted for Differences in Study Design and Quality. <i>PLoS ONE</i> , 2012, 7, e30711.	2.5	49
40	Uncertainty analysis is inherently Bayesian. <i>Value in Health</i> , 2011, 14, 202-203.	0.3	1
41	A note on dealing with missing standard errors in meta-analyses of continuous outcome measures in WinBUGS. <i>Pharmaceutical Statistics</i> , 2011, 10, 374-378.	1.3	23
42	Pharmaceutical Statistics 10th anniversary. <i>Pharmaceutical Statistics</i> , 2011, 10, 475-476.	1.3	0
43	NICE work: how NICE decides what we should pay for. <i>British Journal of General Practice</i> , 2010, 60, 7-8.	1.4	4
44	Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis. <i>Pharmaceutical Statistics</i> , 2009, 8, 150-162.	1.3	8
45	The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation. <i>Pharmaceutical Statistics</i> , 2009, 8, 371-389.	1.3	16
46	Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit. <i>Statistics in Medicine</i> , 2006, 25, 37-53.	1.6	37
47	Bayesian decision procedures for binary and continuous bivariate dose-escalation studies. <i>Pharmaceutical Statistics</i> , 2006, 5, 125-133.	1.3	38
48	Assurance in clinical trial design. <i>Pharmaceutical Statistics</i> , 2005, 4, 187-201.	1.3	211
49	An Evaluation of a Bayesian Method of Dose Escalation Based on Bivariate Binary Responses. <i>Journal of Biopharmaceutical Statistics</i> , 2004, 14, 969-983.	0.8	24
50	On estimators of medical costs with censored data. <i>Journal of Health Economics</i> , 2004, 23, 615-625.	2.7	60
51	Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?. <i>Health Economics (United Kingdom)</i> , 2003, 12, 33-49.	1.7	83
52	Case study in the Bayesian analysis of a cost-effectiveness trial in the evaluation of health care technologies: Depression. <i>Pharmaceutical Statistics</i> , 2003, 2, 51-68.	1.3	9
53	Bayesian methods for design and analysis of cost-effectiveness trials in the evaluation of health care technologies. <i>Statistical Methods in Medical Research</i> , 2002, 11, 469-490.	1.5	55
54	INCORPORATION OF GENUINE PRIOR INFORMATION IN COST-EFFECTIVENESS ANALYSIS OF CLINICAL TRIAL DATA. <i>International Journal of Technology Assessment in Health Care</i> , 2002, 18, 782-790.	0.5	14

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Remacemide versus Carbamazepine in Newly Diagnosed Epilepsy: Comparison by Sequential Analysis. <i>Epilepsy and Behavior</i> , 2002, 3, 140-146.	1.7	37
56	Remacemide versus carbamazepine in newly diagnosed epilepsy. <i>Epilepsy and Behavior</i> , 2002, 3, 405-406.	1.7	3
57	The probability of cost-effectiveness. <i>BMC Medical Research Methodology</i> , 2002, 2, 5.	3.1	39
58	Bayesian cost-effectiveness analysis from clinical trial data. <i>Statistics in Medicine</i> , 2001, 20, 733-753.	1.6	87
59	A framework for cost-effectiveness analysis from clinical trial data. <i>Health Economics (United Kingdom)</i> 17(10):1021-1034, 2002.	1.7	82
60	Inference for the Cost-Effectiveness Acceptability Curve and Cost-Effectiveness Ratio. <i>Pharmacoeconomics</i> , 2000, 17, 339-349.	3.3	78